In all three groups (all samples, stage II only, and stage III only), the plasma levels of CFHR4 (AUC of 0.97 when samples from patients with cancer in the right colon and rectum were compared) and ACSL5 (AUC of 1 between these samples) were found to be much higher in samples from patients with cancer in the right colon compared to the rectum (Table S3). Here, ACSL5 is linked to cancer.